Product Information Sheet for NR-708

Burkholderia pyrrocinia, Strain 2327

Catalog No. NR-708

(Derived from ATCC® 15958™)

For research use only. Not for human use.

Contributor:

ATCC®

Product Description:

Bacteria Classification: *Burkholderiaceae, Burkholderia*
Species: *Burkholderia pyrrocinia,* (type strain)
Strain: 2327; CFBP 4794; CIP 105874; DSM 10685; LMG 14191
Comment: Produces pyrrolnitrin[1-3]

Material Provided:

Each vial contains approximately 0.5 mL of bacterial culture in 0.5X Tryptic Soy Broth supplemented with 10% glycerol.

Packaging/Storage:

NR-708 was packaged aseptically, in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Media:
Tryptic Soy Broth or equivalent
Tryptic Soy Agar or equivalent
Incubation:
Temperature: 30°C
Atmosphere: Aerobic
Propagation:

1. Keep vial frozen until ready for use; then thaw.
2. Transfer the entire thawed aliquot into a single tube of Tryptic Soy Broth.
3. Use several drops of the suspension to inoculate a Tryptic Soy Agar slant and/or plate.
4. Incubate the slant and/or plate at 30°C for 24 hours.

Note:
Colonies are circular, smooth, raised, entire, and translucent.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: *Burkholderia pyrrocinia*, Strain 2327, NR-708."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Arima, K., et al. Production of 3-(2-Nitro-3-chlorophenyl)-4-chloro-pyrrole. U. S. Patent 3,597,325. 03 Aug. 1971.
2. Arima, K., et al. Antibiotic. U. S. Patent 3,699,121. 17 Oct. 1972.
3. Nishida, M., T. Matsubara, and N. Watanabe. "Pyrrolnitrin, a New Antifungal Antibiotic. Microbiological and Toxicological Observations." J. Antibiot., Ser. A 18 (1965): 211–219.
4. Imanaka, H., et al. J. Antibiot., Ser. A 18 (1965): 205–206.

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org
800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org

5. Skerman, V. B., V. McGowan and P. H. Sneath. "Approved Lists of Bacterial Names." Int. J. Syst. Bacteriol. 30 (1980): 225–420.
6. Storms, V., et al. "Polyphasic Characterisation of *Burkholderia cepacia*-Like Isolates Leading to the Emended Description of *Burkholderia pyrrocinia*." System. Appl. Microbiol. 27 (2004): 517–526. PubMed: 15490552.
7. Vandamme, P., et al. "Occurrence of Multiple Genomovars of *Burkholderia cepacia* in Cystic Fibrosis Patients and Proposal of *Burkholderia multivorans* sp. nov." Int. J. Syst. Bacteriol. 47 (1997): 1188–1200. PubMed: 9336927.

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org

800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org